[Concerns on generic enoxaparin use in acute coronary syndrome].
نویسندگان
چکیده
Mailing address: Eduardo Ramacciotti • Vascular Surgery University of Michigan Medical School A570D, MSRB II, 1150 W. Medical Center Dr, Ann Arbor, MI 48109 E-mail: [email protected] Manuscript received July 30, 2010, revised manuscript received July 30, 2010; accepted August 16, 2010.
منابع مشابه
بررسی تأثیر طول مدت زمان تزریق زیرجلدی انوکساپارین بر شدت درد محل تزریق بیماران سندرم حاد کرونری بستری در بخش مراقبت‌های ویژه بیمارستان افشار یزد در سال 1390
Introduction: Enoxaparin is widely used in acute coronary syndrome patients to prevent progression of coronary artery disease. Pain of injection site is the unpleasant result of subcutaneous Enoxaparin injection which causes the patient physical discomfort. One of the nurses’ tasks is applying techniques which cause the reduction of damage to the patient. This clinical trial study investigates ...
متن کاملWill the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?
BACKGROUND One-year follow-up data from the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) trial show that use of low-molecular-weight heparin (enoxaparin) compared with unfractionated heparin in patients hospitalized with unstable angina or non-Q-wave myocardial infarction is associated with a 10% reduction in the cumulative 1-year risk of death, myocard...
متن کاملComparison of the Effects of Enoxaparin and Heparin on Inflammatory Biomarkers in Patients with ST-segment Elevated Myocardial Infarction: A prospective Open Label Pilot Clinical Trial
Objective: Heparin and enoxaparin possess anti-inflammatory properties. We compared the effects of these drugs on inflammatory biomarkers in patients with ST-segment Elevated Myocardial Infarction (STEMI). Method: Thirty four patients with STEMI randomly separated in two groups and received standard doses of heparin and enoxaparin. The serum concentration of Serum Amyloid A (SAA), C-Reactive Pr...
متن کاملEconomic Assessment of Low-Molecular-Weight Heparin (Enoxaparin) Versus Unfractionated Heparin in Acute Coronary Syndrome Patients Results From the ESSENCE Randomized Trial
Background—In the ESSENCE trial, subcutaneous low-molecular-weight heparin (enoxaparin) reduced the 30-day incidence of death, myocardial infarction, and recurrent angina relative to intravenous unfractionated heparin in 3171 patients with acute coronary syndrome (unstable angina or non–Q-wave myocardial infarction). No increase in major bleeding was seen. Methods and Results—Of the 936 ESSENCE...
متن کاملEfficacy and Bleeding Complications Among Patients Randomized to Enoxaparin or Unfractionated Heparin for Antithrombin Therapy in Non–ST-Segment Elevation Acute Coronary Syndromes
UNSTABLE ANGINA AND NON– ST-segment elevation myocardial infarction (UA/ NSTEMI) acute coronary syndromes (ACS) are the most prominent and fastest growing manifestations of coronary heart disease and are the leading causes of death and cardiovascular morbidity in developed countries. While the use of antithrombin therapy has become a guidelinesrecommended standard of care in the treatment of AC...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Arquivos brasileiros de cardiologia
دوره 95 4 شماره
صفحات -
تاریخ انتشار 2010